Article
Stanczak et al. showed that hypersialylation on tumor cells promotes polarization of TAMs towards an immunosuppressive phenotype through interactions with Siglec-E, contributing to disease progression and immune escape. Genetic and therapeutic targeting of the sialoglycan-Siglec axis, either through...

Stanczak et al. showed that hypersialylation on tumor cells promotes polarization of TAMs towards an immunosuppressive phenotype through interactions with Siglec-E, contributing to disease progression and immune escape. Genetic and therapeutic targeting of the sialoglycan-Siglec axis, either through desialylation or targeted removal of Siglec-E, promoted the repolarization of TAMs and supported stronger antitumor immune responses, particularly in the setting of immune checkpoint blockade. These results support further investigation of therapeutic desialylation as a potential immunotherapy.

Show More

Recommended by
Recommendations from around the web and our community.

Nice summary of ⁦@michal_stanczak⁩ and ⁦@LImmunotherapy⁩’s recent publication in ⁦@ScienceTM⁩ on Siglec/sialoglycan axis as target for cancer immune therapy, with the ⁦@Palleon_Pharma⁩ team and us as collaborators. #glycotime